Tool v0
Evidence Tracker
Research discussion only. Not medical advice. This tracker does not recommend any intervention.
| Intervention | Mechanism | Evidence | Boundary | Sources |
|---|---|---|---|---|
| Dasatinib plus quercetin | cellular senescence | human_pilot_open_label | Feasibility signal in a small open-label human pilot; not evidence for general age-related use. Prescription-drug context; adverse-event and contraindication review requires clinician oversight. | dq-ipf-2019 dq-ad-risk-trial |
| mTOR inhibition / rapamycin-class interventions | nutrient sensing and immune function | randomized_human_specific_endpoint | Human evidence is endpoint-specific; immune-response endpoints are not a broad aging outcome. Drug-class risks and dose sensitivity make public self-use claims inappropriate. | rapamycin-immune-2014 hallmarks-2023 |
| Partial cellular reprogramming | epigenetic regulation | preclinical_animal | Preclinical mechanism work; cancer and loss-of-identity risk remain central boundaries. No public human-use pathway from this tracker. | partial-reprogramming-2016 hallmarks-2023 |
| Proteostasis and macroautophagy support | loss of proteostasis and disabled macroautophagy | framework | Framework-level mechanism tag used for organizing sources; not an intervention recommendation. Evidence must be attached per concrete intervention before any stronger claim. | hallmarks-2023 |
Research discussion only. Not medical advice. This tracker does not recommend any intervention.
Sources
- Hallmarks of aging: An expanding universe
- Senolytics in idiopathic pulmonary fibrosis: first-in-human pilot
- NCT05422885: Dasatinib and quercetin in adults at risk for Alzheimer's disease
- mTOR inhibition and immune function in older adults
- In vivo amelioration of age-associated hallmarks by partial reprogramming